Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
Year: 2025
Type: article
Abstract: Bispecific antibodies (BsAbs) have demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma (RRMM) [ 1 , 2 , 3 ]. Three BsAbs are approved for RRMM treatment, including two targeting B-cell maturation antigen (BCMA), teclistamab and elranatamab, and one targeting G protein–coupled receptor class C group 5 member D (GPRC5D), talquetamab. While BsAbs are generally safe and well-tolerated, infectious complications are common during treatment [ 4 , 5 , 6 ].
Source: Blood Cancer Journal
Authors: Eric Jurgens, Tala Shekarkhand, Colin Rueda, David Nemirovsky, Andriy Derkach, Ross S. Firestone, Kevin Miller, Bruno Almeida Costa, Sridevi Rajeeve, Alexander M. Lesokhin, Neha Korde, Carlyn R. Tan, Hamza Hashmi, Hani Hassoun, Kylee Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam Hamadeh, Sergio A. Giralt, Gunjan L. Shah, Heather J. Landau, Michael Scordo, Saad Z. Usmani, Sham Mailankody, Zainab Shahid
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
Funders: U.S. Department of Health and Human Services, Amgen, Bristol-Myers Squibb, Pfizer, GlaxoSmithKline, Sanofi, Gilead Sciences, American Society of Clinical Oncology, Celgene, Memorial Sloan-Kettering Cancer Center, CSL Behring, Angiocrine Bioscience, BeiGene, SkylineDx, Omeros Corporation, Russian Science Foundation, National Institutes of Health, Genentech, Takeda Oncology, Pharmacyclics, Legend Biotech, National Cancer Institute, Janssen Biotech, Daiichi Sankyo Europe
OpenAlex ID: W4415767159